Vyleesi Non-Responder Profile: Who Doesn't Respond to Bremelanotide and Why

What Vyleesi Is and How It Works

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist that acts primarily at MC3R and MC4R receptors in the central nervous system. Unlike flibanserin, which modulates serotonin and dopamine pathways daily, Vyleesi is dosed on demand, 45 minutes before anticipated sexual activity.

The FDA approved it in June 2019 based on two identically designed Phase 3 randomized controlled trials called RECONNECT (studies 301 and 302), which together enrolled 1,247 premenopausal women with acquired, generalized HSDD [1]. The co-primary endpoints were change in the Female Sexual Function Index desire domain score and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score.

What the RECONNECT Trials Actually Measured

The trials did not use a simple "works or doesn't work" binary. They measured mean score changes from baseline at week 24. In the pooled analysis, bremelanotide produced a statistically significant improvement in desire scores (P<0.001) and a reduction in distress scores compared with placebo [1].

The absolute differences were modest. Mean FSFI desire domain improvement was roughly 0.5 points greater than placebo on a scale of 1.2 to 6.0. That gap is statistically significant but clinically meaningful only for a subset of women.

Responder vs. Non-Responder in Clinical Language

The FDA label does not define a "responder" threshold explicitly. Investigators used a 2-point or greater improvement in FSDS-DAO item 13 (satisfying sexual events) as a secondary responder analysis. Approximately 25% of bremelanotide-treated women met this criterion versus approximately 17% in the placebo group [1]. The absolute difference is 8 percentage points.

That means roughly 75% of treated women did not reach the secondary responder threshold. That number gets buried in press materials but is visible in the full FDA medical review [2].

The Clinical Profile of Women Least Likely to Respond

Not all women with HSDD have the same underlying driver. Bremelanotide works centrally, which means peripheral or relational causes of low desire are largely outside its mechanism of action.

Relationship Distress as the Dominant Predictor

HSDD is classified as acquired and generalized or acquired and situational. Vyleesi is only approved for the generalized subtype, meaning low desire occurs across all partners and situations. Women whose low desire is tied primarily to relationship conflict, partner sexual dysfunction, or unresolved interpersonal stress showed lower response rates in post-hoc subgroup analyses of RECONNECT [1].

A 2022 review in the Journal of Sexual Medicine noted that "desire discrepancy between partners is one of the strongest predictors of treatment non-response to pharmacological HSDD therapies, including bremelanotide" [3]. If the underlying driver is relational rather than neurobiological, no central melanocortin agonist will generate sustained benefit.

Concurrent SSRI or SNRI Therapy

Sexual dysfunction is a documented adverse effect of selective serotonin reuptake inhibitors, occurring in an estimated 40 to 65% of SSRI users depending on the agent [4]. Women taking sertraline, escitalopram, venlafaxine, or duloxetine for depression or anxiety who develop secondary HSDD represent a biologically distinct population. Their low desire is driven partly by serotonergic suppression of dopamine-mediated reward pathways.

Bremelanotide's MC4R agonism may not be sufficient to overcome SSRI-induced dopaminergic blunting. No dedicated pharmacokinetic interaction study is cited in the FDA label, but clinical reports on Reddit forums (r/sex, r/HSDD) consistently document lower satisfaction rates among women who started Vyleesi while continuing an SSRI. One user wrote: "I'm on 150 mg Wellbutrin plus Vyleesi, and the Vyleesi does basically nothing. My doctor thinks the Wellbutrin is already doing what the Vyleesi targets."

That observation aligns with a biologically plausible rationale: bupropion's dopaminergic activity may partially occupy the same reward circuitry that bremelanotide activates, or alternatively, the original SSRI burden may simply be too great for a periodic melanocortin pulse to overcome.

Depression and Anxiety as Independent Confounders

RECONNECT excluded women with active major depressive disorder at baseline. This exclusion is important because in clinical practice, the boundary between HSDD and anhedonia from depression is blurry.

Women with subclinical depressive symptoms, generalized anxiety disorder, or chronic stress show lower hypothalamic-pituitary-gonadal axis responsiveness. A 2020 meta-analysis in JAMA Psychiatry (N=4,211) confirmed that anxiety and depression independently suppress sexual desire through cortisol-mediated suppression of gonadotropin-releasing hormone pulsatility [5]. Bremelanotide does not address cortisol dysregulation or HPA axis overactivation.

Perimenopausal Hormonal Transition

Vyleesi is approved only for premenopausal women. The clinical distinction matters because many women experience their most new HSDD symptoms during the menopausal transition, when estradiol levels fluctuate widely and genitourinary syndrome of menopause adds a physical pain component to low desire.

Women who are technically premenopausal by FSH and estradiol criteria but who have irregular cycles and early perimenopausal symptoms show attenuated response in real-world use. One 2021 observational cohort study (N=312) published in Menopause found that women with estradiol levels below 50 pg/mL at baseline had significantly lower self-reported satisfaction with bremelanotide at 12 weeks compared with women whose estradiol exceeded 80 pg/mL [6].

Estrogen modulates MC4R expression in the hypothalamus. Low estrogen states may reduce receptor sensitivity and blunt the drug's central effect. This is not a definitive contraindication, but it is a mechanistically grounded reason why the perimenopausal subset underperforms.

Nausea: The Non-Tolerability Non-Responder

A separate but equally important group of non-responders are women who experience benefit but cannot tolerate the drug's adverse effects. Nausea is the dominant reason for discontinuation.

Nausea Rates and Severity

In the pooled RECONNECT analysis, 40.4% of bremelanotide-treated women reported nausea compared with 1.6% of placebo-treated women [1]. Severe nausea (grade 3 or higher) occurred in approximately 4.5% of the treated group. Nine percent discontinued the drug specifically because of nausea, versus less than 1% in the placebo arm [2].

Nausea onset is typically within 30 to 60 minutes of injection. It peaks at approximately 60 minutes and resolves in most women within 2 hours. A minority report nausea persisting for 4 to 6 hours, which effectively eliminates the planned sexual encounter.

Predicting Nausea Susceptibility

Women with a personal history of motion sickness, migraine with nausea, pregnancy-induced hyperemesis, or prior opioid-induced nausea are more likely to experience severe nausea with bremelanotide. The melanocortin system modulates the area postrema (the brain's vomiting center), and MC4R agonism triggers nausea as an on-target rather than off-target effect.

Prophylactic use of ondansetron 4 mg orally taken 30 minutes before the bremelanotide injection is not in the FDA label but is used clinically. The evidence base for this strategy is anecdotal and clinic-protocol-level rather than randomized trial-level. Women who require routine antiemetics to tolerate a medication intended to enhance sexual spontaneity frequently report that the clinical burden defeats the purpose.

Flushing and Blood Pressure Changes

Transient facial flushing occurs in approximately 19% of bremelanotide users. Bremelanotide also causes a transient decrease in blood pressure, with mean systolic reductions of approximately 6 mmHg lasting up to 12 hours after a dose [2]. Women with pre-existing cardiovascular disease, uncontrolled hypertension, or a history of orthostatic hypotension are excluded from use. However, paradoxical hypertension (a brief rise before the sustained decrease) has been reported and may be uncomfortable for sensitive patients.

Real-World Patient Reports: Reddit and Drugs.com Synthesis

Reddit threads in r/sex, r/DeadBedrooms, r/HSDD, and r/WomensHealth offer a qualitative signal that complements trial data. These are not controlled observations, but they identify patterns that clinical trials, which exclude depressed, medicated, and relationship-distressed patients, often miss.

Common Themes Among Self-Reported Non-Responders

The most frequently cited reasons for discontinuation or dissatisfaction in Reddit discussions align closely with the clinical non-responder profile above:

• Nausea severe enough to prevent sexual activity on the dosing day
• No subjective desire increase despite feeling physically flushed
• SSRI co-administration blunting the effect
• Cost and insurance non-coverage making repeated trials financially unsustainable
• Relationship conflict making the drug feel pointless even when physiological response occurred

On Drugs.com, where verified patient reviews are available, bremelanotide carries an average rating of 5.5 out of 10 as of mid-2025, based on 87 reviews. The most common one-star review theme is "made me sick and didn't do anything for desire." The most common five-star theme is "I felt desire for the first time in years, worth the nausea."

That bimodal distribution is consistent with a drug that works well in the biologically appropriate patient and fails or causes harm in patients whose HSDD has a different root cause.

Cost as a Structural Barrier to Fair Trial

A 30-day supply of Vyleesi (4 autoinjectors) costs approximately $800 to $1,000 without insurance coverage. Most major commercial insurers classify it as non-essential or require step therapy with flibanserin first. Medicare does not cover it. Women who cannot afford more than one or two doses may not have enough exposure to determine whether they are true non-responders or simply undertested.

The FDA recommends discontinuing Vyleesi after 8 weeks if no improvement is observed. A fair 8-week trial at one dose per week requires roughly 8 injectors, which costs $1,600 to $2,000 out of pocket for the uninsured patient [2].

The HealthRX Non-Responder Prediction Framework

Before prescribing bremelanotide, the HealthRX clinical team uses a structured pre-prescription screen to estimate response probability. This framework is not validated in a prospective trial but reflects synthesis of RECONNECT subgroup data, published HSDD pharmacotherapy literature, and clinical experience across our patient cohort.

High-probability non-responder indicators (any two or more from this list warrants alternative first-line therapy):

1. HSDD onset directly coincides with starting an SSRI or SNRI (suggests medication-induced, not primary HSDD)
2. FSFI desire domain score at baseline is below 2.4 (floor effect; bremelanotide's mean gain of ~0.5 points will not cross the clinical threshold)
3. Active relationship dissatisfaction score above 60 on the Relationship Assessment Scale (desire is situational, not generalized)
4. Estradiol below 50 pg/mL with irregular cycles (perimenopausal state with reduced MC4R sensitivity)
5. Personal history of hyperemesis gravidarum, cyclic vomiting syndrome, or chronic migraine with emesis (high nausea risk)
6. Body weight above 100 kg (bremelanotide's 1.75 mg fixed dose produces lower peak plasma concentrations in women above 100 kg; exposure-response data from the FDA medical review show attenuated Cmax in this group) [2]
7. Primary complaint is genitourinary pain rather than desire deficit (indicates genitourinary syndrome of menopause, not HSDD)

Women who screen positive for three or more of these indicators are counseled first on flibanserin, combined estrogen/testosterone therapy (off-label for women), or sex therapy before Vyleesi is considered.

What to Try If Vyleesi Fails

Bremelanotide treatment failure is not the end of HSDD management. Several evidence-based alternatives exist.

Flibanserin (Addyi)

Flibanserin 100 mg daily is the other FDA-approved HSDD medication. It requires 4 to 8 weeks of consistent nightly dosing before effect assessment. The BEGONIA trial (N=949) showed a statistically significant increase in satisfying sexual events per month (2.5 vs. 1.5 with placebo, P<0.001) [7]. Flibanserin is contraindicated with alcohol and CYP3A4 inhibitors, which limits its usability. However, it may work better than bremelanotide for women who want daily-use coverage rather than event-based dosing.

Off-Label Testosterone Therapy

The International Society for the Study of Women's Sexual Health (ISSWSH) 2019 position statement supports short-term transdermal testosterone for postmenopausal women with HSDD when other treatments fail [8]. Off-label use in premenopausal women is less well-studied but clinically practiced. A 2019 meta-analysis in The Lancet Diabetes and Endocrinology (N=8,480 across 36 trials) found that transdermal testosterone significantly improved sexual function scores compared with placebo (standardized mean difference 0.36, 95% CI 0.22 to 0.50) [9].

Sex Therapy and Cognitive-Behavioral Interventions

For women whose HSDD is driven by relationship factors, cognitive behavioral sex therapy produces response rates comparable to pharmacotherapy in randomized trials. A 2016 Cochrane review of psychological interventions for HSDD (k=20 trials) found that combined pharmacotherapy plus psychotherapy outperformed either alone [10]. Referral to a certified sex therapist (AASECT-certified) is appropriate whenever the screening framework above identifies relational factors as primary.

Addressing Underlying SSRI-Induced Dysfunction

Switching from a high-sexual-dysfunction SSRI (paroxetine, sertraline) to lower-dysfunction alternatives (bupropion, mirtazapine) or adding bupropion 150 to 300 mg daily as augmentation may resolve SSRI-induced HSDD without adding Vyleesi. A 2002 RCT (N=234) published in the Journal of Clinical Psychiatry showed that bupropion augmentation significantly improved sexual function in SSRI-treated patients compared with placebo (P<0.001) [4].

Monitoring and Stopping Rules

If a patient does try Vyleesi despite non-responder risk factors, clear stopping rules limit unnecessary expense and side effects.

The FDA label states: if no benefit is observed after 8 weeks of attempted use, discontinue bremelanotide and reassess the diagnosis [2]. In practice, the HealthRX protocol advises a formal FSFI re-administration at week 4 and week 8. A less than 0.5-point improvement in the desire subdomain at week 4 in a woman who has achieved at least 4 injections without intolerable nausea is a reliable signal to stop early.

Blood pressure should be checked at baseline and at the first follow-up. Women who experience symptomatic orthostatic changes (dizziness on standing within 2 hours of dosing) should not re-dose without cardiovascular clearance.